Cyclopharm

Cyclopharm Stock-Based Compensation

The Stock-Based Compensation (SBC) of Cyclopharm (CYC.AX) as of Nov 12, 2026 is 360,897.00 AUD. In the previous year, Stock-Based Compensation (SBC) was 524,192.00 AUD — a change of -31.15% (lower).

Stock-Based Compensation

360,897.00AUD

YoY

-31.15%

Last updated:

Stock-Based Compensation (SBC) of Cyclopharm is 2024 360,897.00 AUD. Stock-Based Compensation (SBC) of Cyclopharm was 2023 524,192.00 AUD. It decreases by -31.15% lower compared to the previous year.

The Cyclopharm Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2017
21,416.00 AUD
Jan 1, 2018
37,967.00 AUD
Jan 1, 2019
378,368.00 AUD
Jan 1, 2020
795,600.00 AUD
Jan 1, 2021
756,588.00 AUD
Jan 1, 2022
648,202.00 AUD
Jan 1, 2023
524,192.00 AUD
Jan 1, 2024
360,897.00 AUD
The Cyclopharm Stock-Based Compensation history
YEARStock-Based CompensationYoY
360,897.00AUD-31.15%
524,192.00AUD-19.13%
648,202.00AUD-14.33%
756,588.00AUD-4.90%
795,600.00AUD+110.27%
378,368.00AUD+896.57%
37,967.00AUD+77.28%
21,416.00AUD-80.13%
107,777.00AUD-17.47%
130,586.00AUD+389.56%
26,674.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cyclopharm Stock analysis

What does Cyclopharm do? Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyclopharm stock

Stock-Based Compensation (SBC) of Cyclopharm is 360,897.00 AUD in 2024.

Stock-Based Compensation (SBC) of Cyclopharm changed from 524,192.00 AUD to 360,897.00 AUD, representing a -31.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Cyclopharm since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Cyclopharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cyclopharm

All Key Metrics — Cyclopharm